TW201102060A - Anti-biofilm carbonate compounds for use in oral care compositions - Google Patents
Anti-biofilm carbonate compounds for use in oral care compositions Download PDFInfo
- Publication number
- TW201102060A TW201102060A TW099109766A TW99109766A TW201102060A TW 201102060 A TW201102060 A TW 201102060A TW 099109766 A TW099109766 A TW 099109766A TW 99109766 A TW99109766 A TW 99109766A TW 201102060 A TW201102060 A TW 201102060A
- Authority
- TW
- Taiwan
- Prior art keywords
- care composition
- oral
- acid
- group
- oral health
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 92
- 230000003214 anti-biofilm Effects 0.000 title description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 title description 3
- -1 carbonate compound Chemical class 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 35
- 210000000214 mouth Anatomy 0.000 claims abstract description 27
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 27
- 230000008901 benefit Effects 0.000 claims abstract description 22
- 239000002207 metabolite Substances 0.000 claims abstract description 22
- 150000001875 compounds Chemical class 0.000 claims description 43
- 230000036541 health Effects 0.000 claims description 37
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 239000004094 surface-active agent Substances 0.000 claims description 17
- 125000001931 aliphatic group Chemical group 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- 239000002562 thickening agent Substances 0.000 claims description 14
- 239000004599 antimicrobial Substances 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- 230000004060 metabolic process Effects 0.000 claims description 12
- 125000004122 cyclic group Chemical group 0.000 claims description 11
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 10
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 10
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 10
- 230000007407 health benefit Effects 0.000 claims description 10
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 10
- 230000000845 anti-microbial effect Effects 0.000 claims description 8
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 239000004474 valine Substances 0.000 claims description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 5
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 5
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 5
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims description 5
- 229930010555 Inosine Natural products 0.000 claims description 5
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 5
- 239000004473 Threonine Substances 0.000 claims description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 5
- 239000003082 abrasive agent Substances 0.000 claims description 5
- 239000000853 adhesive Substances 0.000 claims description 5
- 230000001070 adhesive effect Effects 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000013355 food flavoring agent Nutrition 0.000 claims description 5
- 229940029575 guanosine Drugs 0.000 claims description 5
- 229960003786 inosine Drugs 0.000 claims description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 5
- 241000894007 species Species 0.000 claims description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 5
- 230000004143 urea cycle Effects 0.000 claims description 5
- LVRFTAZAXQPQHI-UHFFFAOYSA-N 2-hydroxy-4-methylvaleric acid Chemical compound CC(C)CC(O)C(O)=O LVRFTAZAXQPQHI-UHFFFAOYSA-N 0.000 claims description 4
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- 108010053070 Glutathione Disulfide Proteins 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 4
- 229960001231 choline Drugs 0.000 claims description 4
- 239000003599 detergent Substances 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- 229960002989 glutamic acid Drugs 0.000 claims description 4
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 claims description 4
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 4
- 239000003765 sweetening agent Substances 0.000 claims description 4
- 229940116269 uric acid Drugs 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 229940090898 Desensitizer Drugs 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- OJDNFXUNDNXMPS-UHFFFAOYSA-N guanidine;2-sulfanylacetic acid Chemical compound NC(N)=N.OC(=O)CS OJDNFXUNDNXMPS-UHFFFAOYSA-N 0.000 claims description 2
- 235000019659 mouth feeling Nutrition 0.000 claims description 2
- 239000007800 oxidant agent Substances 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 241000233805 Phoenix Species 0.000 claims 1
- 238000004945 emulsification Methods 0.000 claims 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 claims 1
- 235000015170 shellfish Nutrition 0.000 claims 1
- 230000002087 whitening effect Effects 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 abstract description 20
- 230000015572 biosynthetic process Effects 0.000 abstract description 9
- 230000002222 downregulating effect Effects 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 150000003254 radicals Chemical class 0.000 abstract description 5
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 4
- 230000000854 inhibitional effect Effects 0.000 abstract description 3
- 150000005840 aryl radicals Chemical class 0.000 abstract 1
- 230000018612 quorum sensing Effects 0.000 abstract 1
- 239000010455 vermiculite Substances 0.000 description 15
- 229910052902 vermiculite Inorganic materials 0.000 description 15
- 235000019354 vermiculite Nutrition 0.000 description 15
- 239000003963 antioxidant agent Substances 0.000 description 14
- 235000006708 antioxidants Nutrition 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 12
- 230000003078 antioxidant effect Effects 0.000 description 12
- 239000000551 dentifrice Substances 0.000 description 11
- 239000000606 toothpaste Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 229940034610 toothpaste Drugs 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 239000004575 stone Substances 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 108010024636 Glutathione Proteins 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 208000002925 dental caries Diseases 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 4
- 241000588653 Neisseria Species 0.000 description 4
- IOSLINNLJFQMFF-XMMPIXPASA-N [(2R)-1-[[4-[[3-[(4-fluorophenyl)methylsulfanyl]phenoxy]methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound FC1=CC=C(CSC=2C=C(OCC3=CC=C(CN4[C@H](CCC4)CO)C=C3)C=CC=2)C=C1 IOSLINNLJFQMFF-XMMPIXPASA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 229940125900 compound 59 Drugs 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000003239 periodontal effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000186361 Actinobacteria <class> Species 0.000 description 3
- 241000186046 Actinomyces Species 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 3
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 230000002272 anti-calculus Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000032770 biofilm formation Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 3
- 235000011180 diphosphates Nutrition 0.000 description 3
- 230000006806 disease prevention Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000007565 gingivitis Diseases 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 150000002989 phenols Chemical class 0.000 description 3
- 229940048084 pyrophosphate Drugs 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010013082 Discomfort Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- DNIDCQUDANKQTL-ILFMMJCVSA-N Gentioside(xanthone) Chemical compound COC1=CC2=C(C=C1)OC3=CC(=CC(=C3C2=O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO[C@H]5[C@@H]([C@H]([C@@H](CO5)O)O)O)O)O)O DNIDCQUDANKQTL-ILFMMJCVSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000004075 cariostatic agent Substances 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229930002875 chlorophyll Natural products 0.000 description 2
- 235000019804 chlorophyll Nutrition 0.000 description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 2
- 239000002826 coolant Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 235000012661 lycopene Nutrition 0.000 description 2
- 229960004999 lycopene Drugs 0.000 description 2
- 239000001751 lycopene Substances 0.000 description 2
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 239000010695 polyglycol Substances 0.000 description 2
- 229920000151 polyglycol Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- BHHYHSUAOQUXJK-UHFFFAOYSA-L zinc fluoride Chemical compound F[Zn]F BHHYHSUAOQUXJK-UHFFFAOYSA-L 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- LVRFTAZAXQPQHI-RXMQYKEDSA-N (R)-2-hydroxy-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](O)C(O)=O LVRFTAZAXQPQHI-RXMQYKEDSA-N 0.000 description 1
- LVRFTAZAXQPQHI-YFKPBYRVSA-N (S)-2-hydroxy-4-methylpentanoic acid Chemical compound CC(C)C[C@H](O)C(O)=O LVRFTAZAXQPQHI-YFKPBYRVSA-N 0.000 description 1
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 102000008482 12E7 Antigen Human genes 0.000 description 1
- 108010020567 12E7 Antigen Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- BDHVDYUIWOIODW-UHFFFAOYSA-N 2-butyl-4-nonylphenol Chemical compound CCCCCCCCCC1=CC=C(O)C(CCCC)=C1 BDHVDYUIWOIODW-UHFFFAOYSA-N 0.000 description 1
- XHKUTQNVGAHLPK-UHFFFAOYSA-N 2-fluorocyclohexa-2,5-diene-1,4-dione Chemical compound FC1=CC(=O)C=CC1=O XHKUTQNVGAHLPK-UHFFFAOYSA-N 0.000 description 1
- LPYUENQFPVNPHY-UHFFFAOYSA-N 3-methoxycatechol Chemical compound COC1=CC=CC(O)=C1O LPYUENQFPVNPHY-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- ZUGAOYSWHHGDJY-UHFFFAOYSA-K 5-hydroxy-2,8,9-trioxa-1-aluminabicyclo[3.3.2]decane-3,7,10-trione Chemical compound [Al+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZUGAOYSWHHGDJY-UHFFFAOYSA-K 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910021593 Copper(I) fluoride Inorganic materials 0.000 description 1
- 229910021594 Copper(II) fluoride Inorganic materials 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 240000005183 Lantana involucrata Species 0.000 description 1
- 235000013628 Lantana involucrata Nutrition 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 240000002624 Mespilus germanica Species 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- 101100447665 Mus musculus Gas2 gene Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000227633 Ocotea pretiosa Species 0.000 description 1
- 235000004263 Ocotea pretiosa Nutrition 0.000 description 1
- DJNTZVRUYMHBTD-UHFFFAOYSA-N Octyl octanoate Chemical compound CCCCCCCCOC(=O)CCCCCCC DJNTZVRUYMHBTD-UHFFFAOYSA-N 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000125380 Terminalia tomentosa Species 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000011795 alpha-carotene Substances 0.000 description 1
- 235000003903 alpha-carotene Nutrition 0.000 description 1
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 229940024548 aluminum oxide Drugs 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000002968 anti-fracture Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- OYLGJCQECKOTOL-UHFFFAOYSA-L barium fluoride Chemical compound [F-].[F-].[Ba+2] OYLGJCQECKOTOL-UHFFFAOYSA-L 0.000 description 1
- 229910001632 barium fluoride Inorganic materials 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical class C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229910000420 cerium oxide Inorganic materials 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 208000034391 chronic adult periodontitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000001277 chronic periodontitis Diseases 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000001279 citrus aurantifolia swingle expressed oil Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- GWFAVIIMQDUCRA-UHFFFAOYSA-L copper(ii) fluoride Chemical compound [F-].[F-].[Cu+2] GWFAVIIMQDUCRA-UHFFFAOYSA-L 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical class C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- CYUUZGXOQDCCGH-UHFFFAOYSA-N dodecyl dodecanoate Chemical compound CCCCCCCCCCCCOC(=O)CCCCCCCCCCC CYUUZGXOQDCCGH-UHFFFAOYSA-N 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000004673 fluoride salts Chemical class 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- KSQVTHWVSWYGNQ-UHFFFAOYSA-N gentioside Natural products C=1C(O)C(O)(C)C2C=1C(C(=O)OC)=COC2OC1OC(CO)C(O)C(O)C1O KSQVTHWVSWYGNQ-UHFFFAOYSA-N 0.000 description 1
- 210000002816 gill Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000010651 grapefruit oil Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Substances OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910001506 inorganic fluoride Inorganic materials 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 1
- 229940048848 lauryl glucoside Drugs 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- GCICAPWZNUIIDV-UHFFFAOYSA-N lithium magnesium Chemical compound [Li].[Mg] GCICAPWZNUIIDV-UHFFFAOYSA-N 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 229910012375 magnesium hydride Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000007884 metabolite profiling Methods 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 230000001431 metabolomic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Chemical compound [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 description 1
- 229940099402 potassium metaphosphate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 208000008655 root caries Diseases 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229910000275 saponite Inorganic materials 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical class [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- BFDWBSRJQZPEEB-UHFFFAOYSA-L sodium fluorophosphate Chemical group [Na+].[Na+].[O-]P([O-])(F)=O BFDWBSRJQZPEEB-UHFFFAOYSA-L 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940080728 steareth-30 Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
201102060 六、發明說明: 【發明所屬之技術領域】 發明之領域 本發明係關於口腔組成物,其包含抑制牙斑及與齲齒相關 之奈斯隆氏放線菌(左⑽必)·)生長及生物膜形成之碳 酸酯化合物。 【先前技術】 發明之背景 麵齒及牙周疾病係影響人類之最通常之慢性感染疾病之 兩種及經常係與於牙齒表面上如一種生物膜形成之牙斑相 關。牙斑係經由多種之細菌之連續之附著而產生,其係視涉 及之物種及表面組成物而疋。奈斯隆氏放線菌( (A⑽灯/w—7))係革蘭氏染色陽性,桿形狀之細 菌,其係於佔據齒腔及於牙齒之表面形成聚落之第一種物種 中。奈斯隆氏放線菌係已經涉及於牙周之疾病及齒根齲齒 (root caries )中 〇 群體捃度感應係於細菌細胞之間之細胞間傳達信息之一 種方法,其容許細菌控制基因表現及以一群組對應於群體密 度。佔據口腔之細菌,包括奈斯隆氏放線菌,使用群體密度 感應系統以調節若干生理之料,包括外來之去氧核糖核酸 (DNA)之併入、耐酸性、生物膜形成、及毒性。因此,經 由群體密度麵,奈氏放麵可使彼等之生理發揮最大 =用以1應於%境之刺激及可行為如_種集合體,藉以致成 伟主之I乂佳之形成聚落’進化如—種物種,及改良對於機 201102060 械、物理、及化學壓迫力之回應。結果,於生物膜中之細菌 對於殺菌劑及宿主防禦具有提高之抗性。 【發明内容】 發明之概述 本發明包含口腔保健組成物及用於經由群體密度感應抑 制作用及/或殺菌劑活性而抑制口腔生物膜之生長及形成之 方法。 於某些具體實施例中,本發明揭示一種口腔保健組成物, 其包含治療有效量之至少一種式1之碳酸s旨化合物及至少一 種賦形劑: 〇 式1 其中, R!及R2獨立地係:脂族基團、羥基脂族基團、 或芳基基團。 於某些具體實施例中,R!係自具有多達10個碳原子之環狀 或分枝之脂族基團選出及R2係自線性或分枝之羥基脂族基 團選出。於某些具體實施例中,R!係未經取代之芳基基團及 R2係自具有多達1〇個碳原子之線性或分枝之羥基脂族基團 選出。 於某些具體實施例中,本發明揭示一種提供口腔保健利益 之方法,其包含將一種包含治療有效量之至少一種式1之碳 酸酯化合物及至少一種賦形劑之口腔保健組成物塗敷至口 6 201102060 腔。於某些具體實施例中,該等口腔保健利益包括生物膜抗 -附著、抗-氧化劑、及抗-微生物利益。 於某些具體實施例中,本發明揭示一種向上調節或向下調 節牙周疾病代謝產物之方法,其包含將一種包含治療有效量 之至少一種式1之碳酸酯化合物及至少一種賦形劑之口腔保 健組成物塗敷至口腔。於某些具體實施例中,該口腔保健組 成物向上調節或向下調節至少一種自下列選出之分子:一種 經由胺基酸代謝作用而產生之化合物、一種於尿素循環中產 生之化合物、一種於麩胱甘肽轉化作用中產生之化合物、— 種於脂質代謝作用中產生之化合物、一種於碳水化合物代謝 作用中產生之化合物、一種經由核酸代謝作用而產生 物、維生素類、及辅因子類。 化5 發明之詳細說明 範=始至終使用’範圍係作為速記之文字使用以敍述” 為每—種及所有之值。可選擇於該範圍内之任何值;;
之端點。此外’於本文中引用之所有參 J 匕以引用之方式完整地併入。 干係轎 如於本文中使用,術語“生物膜形成” 至表面及多層之細胞之其後之發展/ ^生物之附著 山如於本文中使用’術語“牙斑”表示於 肷入於細菌與唾液來源之聚合 中:表面上發現, 群落(主要地細菌此外,之【種之微生物 菌,,表示奈斯隆氏放《,相關之奈斯隆氏放線 如於太其牙斑之—種組份。 使用,術語“抑制作用,,表示至少與 7 201102060 之細菌(例如,奈斯隆氏放線菌)生長及生物膜形成之降低。 如於本文中使用,術語“口腔保健”表示影響口腔或相關 之醫療情況之疾病及不適之治療及預防之處理。口腔之疾病 及不適包括,但不限於:齲齒、牙周之疾病(例如,齒齦炎、 成人牙周膜炎、早發性(early-onset)牙周膜炎、及其他)、 黏膜感染(例如,口腔念珠菌病、單純癌療病毒感染、復發 之口瘡之潰瘍、及其他)、口腔及咽之癌症、及癌前之病灶。 如於本文中使用,術語“群體密度感應”表示基因表現對 應於細菌密度之控制。細菌之細胞利用分泌之發訊號之分子 而於生物膜之細胞之中傳達訊息。通常,革蘭氏染色陽性細 菌,包括奈斯隆氏放線菌,利用小之肽類作為效應子發射訊 號之分子。 如於本文中使用,術語“治療有效量”表示,足夠高以 提供受處理之主體之情況之有意義之正面改良之一種組成 物之量。一種“治療有效量”,如於本文中使用,包括預防 疾病之量(例如,對於避免或保護對抗麟齒及相關之疾病、 及其症狀有效之量),及對於減輕或治療齲齒、相關之疾病、 及其症狀有效之量。 如於本文中使用,術語“健康之口腔狀態”意表齒齦炎及 /或牙周之疾病之不存在。 如於本文中使用,術語“牙周之疾病”意表牙周組織(其 包括齒齦、或齒齦組織;牙骨質、或牙齒之根部之外層;牙 槽之骨、或固定牙齒進入其中之骨穴;及牙周之韌帶(其等 係於牙骨質與牙槽之骨之間延伸之連結之組織纖維)之炎症 8 201102060 及包括齒齦炎。 ,本發明包含口腔保健組成物及用於經由群體密度感應抑 制作用及/或殺菌劑活性而抑制口腔生物膜之生長及形成之 方法。 1 · 口腔保健組成物 於某些具體實施例中,本發明揭示一種用於提供口腔健康 保健利益之口腔保健組成物。於某些具體實施例中,:發明 揭不一種用於提供至少一種選自下列之口腔健康保健利益 之口腔保健組成物:口腔生物膜抗-附著、抗_氧化劑、及抗_ ,生物之利益。於某些具體實施例中,本發明揭示—種用於 ,供多種口腔健康保健利益之口腔保健組成物。於某些具體 只施例中,本發明揭示一種用於提供口腔健康保健利益之口 腔保健組成物’該等利益包括口腔生物膜抗-附著、抗-氧化 ^、及抗-微生物之利益。 於某些具體實施例中,一種根據本發明之口腔保健組成物 向上調節及/或向下調節至少一種牙周疾病之代謝產物。於某 二具體貫施例中,本發明揭示一種用於向上調節至少一種牙 周疾病之代謝產物之口腔保健組成物。於某些具體實施例 中’本發明揭示一種用於向下調節至少一種牙周疾病之代謝 產物之口腔保健組成物。於某些具體實施例中,本發明揭示 一種用於向上調節及/或向下調節多種牙周疾病之代謝產物 之口腔保健組成物。 於某些具體實施例中,一種根據本發明之口腔保健組成物 係適合於口腔中之使用。於某些具體實施例中,該口腔保健 201102060 組成物係適合於經由口腔之攝取。於某些具體實施例中,一 種根據本發明之口腔保健組成物包含,但不限於:乳脂、凝 膠、糊劑、泡沫、乳液、懸浮液、氣溶膠、喷霧、漱口藥、 醫藥品、膠囊、顆粒、藥片、鍵劑、甜食及口香糖。於某些 具體實施例中’該口腔保健組成物係一種潔齒劑組成物。於 某些具體實施例中,該潔齒劑組成物係一種自下列選出之分 子:牙膏、凝膠、漱口藥、牙線、粉末、附著膠之條片、牙 刷、及其類似物。於某些具體實施例中,根據本發明之潔齒 劑組成物係一種牙膏。 A. 碳酸酯化合物 於某些具體實施例中,本發明揭示一種口腔保健組成物, 其包含治療有效量之至少一種式1之碳酸酯化合物及至少— 種賦形劑。適合於本發明中之使用之碳酸酯化合物符合式1: r,〇vY^〇、r2 0 式1 其中, 及R2獨立地係:脂族基團、羥基脂族基團、 或芳基基團。 於某些具體實施例中,一種根據本發明之口腔保健組成物 包含至少一種式1之碳酸酯化合物,其中心及!^獨立地係: 環狀或分枝之脂族基團、線性或分枝之羥基脂族基團、或未 經取代之芳基基團。於某些具體實施例中,一種根據本發明 之口腔保健組成物包含至少一種式1之碳酸酯化合物,其中 201102060
Ri及R2獨立地係.具有多達10個碳原子之環狀或分枝之脂族 基團、具有多達個碳原子之線性或分枝之羥基脂族基團、 或未經取代之芳基基團。 於某些具體實施例中,Ri係環狀或分枝之脂族基團。於某 些具體實施例中,Ri係具有多達10個碳原子之環狀或分枝之 脂族基團。於某些具體實施例中,心係具有於5與10個碳原 子之間之環狀或分枝之脂族基團。於某些具體實施例中,R! 係具有於5與8個碳原子之間之環狀或分枝之脂族基團。於某 些具體實施例中,1^係芳族環。於某些具體實施例中,心係 經取代或未經取代之芳基基團。於某些具體實施例中,艮係 未經取代之芳基基團。 於某些具體實施例中,尺2係線性或分枝之羥基脂族基團。 於某些具體實施例中,R2係具有多達10個碳原子之線性或分 枝之沒基脂族基團。於某些具體實施例中,R2係具有於6與 10個碳原子之間之線性或分枝之羥基脂族基團。 於某些具體實施例中,&係自具有多達10個碳原子之環狀 或分枝之脂族基團選出及尺2係自線性或分枝之羥基脂族基 團選出。於某些具體實施例中,Ri係未經取代之芳基基團及 尺2係自具有多達10個碳原子之線性或分枝之羥基脂族基團 選出。 於某些具體實施例中,一種根據本發明之口腔保健組成物 包含至少一種式1之碳酸酯化合物,其中該至少一種碳酸酯 化合物係: 201102060
於某些具體實施例中,一種根據本發明之口腔保健組成物 包含至少一種式1之碳酸酯化合物,其中該至少一種碳酸酯 化合物係:
於某些具體實施例中,一種根據本發明之口腔保健組成物 包含至少一種式1之碳酸酯化合物,其中該至少一種碳酸酯 化合物係:
OH
於某些具體實施例中,一種根據本發明之口腔保健組成物 以0.05重量%至5重量%之治療有效量包含該至少一種式1 之碳酸酯化合物。於某些具體實施例中,該至少一種碳酸酯 化合物係以0.1重量%至1.5重量%之有效量存在。於某些 具體實施例中,該至少一種碳酸酯化合物係以〇·3重量%至 1.2重量%之有效量存在。 12 201102060 β· 賦形劑 於某些具月豆只轭例中’ 一種根據本發明之口腔保健組成物 包S至少一種賦形劑。適合於本發明中之使用之賦形劑包括 於口腔保健組成物t係習用地使賴且不改變式i之碳酸酿 化合物之功效之任何化合物。 對於根據本發明之口腔組成物,適合之賦形劑可係自下列 選出:防腐劑、磨擦劑(光滑劑)、另外之抗菌劑、發炎_抑 制劑、刺激-防止劑、刺激_抑制劑、另外之抗微生物劑、抗 氧化劑、黏合劑、(礦物)塡充劑、緩衝劑、載體材料、鉗 合劑(鉗合物形成劑)、清潔劑、保健劑、表面_活性物質、 乳化劑、酵素、泡沫_形成劑、泡沐安定劑、泡殊促進劑、 膠化劑、凝膠-形成劑、漂白劑、嗅覺-及/或味覺-調節劑、嗅 覺-及/或味覺-降低劑、嗅覺-及/或味覺_增進劑、塑化劑、(黏 膜)/皮膚冷卻劑(冷卻之物質)、(黏膜)/皮膚鎮痛劑、(黏 膜)/皮膚洗淨劑、(黏膜)/皮膚保健劑 ' (黏膜)/皮膚治癒 劑、黏膜-保護劑、安定劑、懸浮劑、維生素、著色劑、顏 色-保護劑、顏料、界面活性劑、電解質、聚矽氧衍生物、 多元醇、碳酸辑、填酸氫轉、氧化銘、氟化物、鋅、錫、斜、 鈉及鳃鹽、焦磷酸鹽、氫氧磷灰石。 於某些具體實施例中,一種根據本發明之口腔保健組成物 包含至少一種賦形劑,其中該至少一種賦形劑係自下列選 出··界面活性劑、減敏感劑、增白劑、牙石控制劑、抗菌劑、 包括矽石之磨擦物、黏合劑及增稠劑、清潔劑、黏附劑、泡 沫調節劑、pH修飾劑、口腔-感覺劑、增甜劑、調味劑、著 13 201102060 色劑、防腐劑、其等之組合物、及其類似物。 1 · 調味劑 於某些具體實施例中,一種根據本發明之口腔保健組成物 包含一種調味劑。於某些具體實施例中,該調味劑係一種自 下列選出之分子:黏膜冷卻劑、黏膜溫暖劑、強烈味道物質 (sharp-tasting substances)、增甜劑、糖取代物、有機或無 機之酸化劑(例如,蘋果酸、乙酸、檸檬酸、酒石酸、磷酸)、 苦味素(例如,奎寧、咖啡鹼、擰檬苦素、龍膽苷、律草酮 (humolones)、蛇麻草素、兒茶酚、單寧酸)、可食用之礦物 鹽(例如,氣化鈉、氯化鉀、氣化鎂及磷酸鈉)、香精油(例 如’綠薄荷、胡椒薄荷、鹿蹄草、黃樟、丁香、鼠尾草、桉、 馬鬱蘭、肉桂 '檸檬、萊姆、柚子、及橙之油)、薄荷腦、 香草芹酮、大茴香腦、及其等之組合物。 2. 磨擦劑 適合於本發明中之使用之磨擦劑包括矽石材料及特別地 具有低於100立方厘米/100克矽石(及較佳地於45立方厘 米/100克至低於70立方厘米/1〇〇克矽石之範圍内)之油吸 收值之矽凝膠及沈澱之非晶形矽石。油吸收值係使用ASTM Rub-Out Method D281而測量。於本發明之實施中特別有用 之低油吸收矽石磨擦劑係於商品名稱Sylodent® XWA下銷 售(Davison Chemical Division of W. R. Grace & Co” Baltimore,Md. 21203 )。Sylodent® 650 XWA,一種由具有 29 %重量比之水含量於直徑中平均7至10微米、及低於70立 方厘米/100克矽石之油吸收之膠體矽石之粒子組成之矽石 14 201102060 水凝膠,係於本發明之實施中有用之低油吸收矽石磨擦劑之 一種較佳之貫例。於本發明之實施中特別有用之另一種低油 吸收矽石磨擦劑係於商品名稱Dp_丨05tm下銷售(M Huber
Chemicals Division,Havre de Grace, Md. 21078 ) ’ 其係一種具 有5至12微米之平均粒度分布及於50至70立方厘米/100 克之範圍内之油吸收之沈澱之非晶形矽石。於本發明之實施 中可使用之其他磨擦劑包括具有多達2G微米之平均粒度之 沈澱之矽石,諸如 Ze〇dent(g) n5 (J M Huber chemicals
Dmsum,Hawe de Grace,Md. 21078)、或 Sylodent® 783 (Davison Chemical Divisi〇n 〇f w R & 〜哪町)、偏 磷酸鈉、偏磷酸鉀、磷酸三鈣、二水合之磷酸二鈣、矽酸鋁、 锻銘氧、膨土或其㈣f之材料、或其等之組合物。 =某些具體實施射,—種根據本發明之口腔保健組成物 。二種磨擦劑賦形劑。於某些具體實施例中’該磨擦劑職 刪:於某些具體實施例中,該石夕石材料係 ^ 彳;米至12微米之範圍内之平均粒度之膠體粒子。 =些具體實施例中,該膠體粒子具有於5至1()微米之範 圍内^平均粒度及當如-種5重量㈣液測量時於4至1〇 i t也6至9)之ΡΗ範圍。於某些具體實施例中,該石夕 石材料係-種低油吸㈣石磨_。於某純體實施例中, 該低油吸收秒石磨擦劑係於5重量%至40重量%之濃度存 在於本發明之α腔減喊物巾。於某些具體實施例中,該 低油吸切石磨擦劑係於1G重量%至3()重量%之濃 在。 201102060 料些具體實施例中,該磨擦劑__—種自 之^ ··石夕酸、碳酉欠約、碟酉_、叙氧化物及/或氫氧鱗灰 =出 偏私酸納、偏石舞酸钟、碟酸三柄、-p人 " 肌胺酸月桂醋自、及椰油醯胺基丙基甜菜卜 (cocamidopropylbetaine))、及其他矽質之材料双 組合物。 /、寻之 於某些具體實施例中’於製備本發明之口腔保健組成物 中’該磨擦劑賦形劑可係、如唯-之磨擦物個別地或於與盆他 已知之潔齒劑磨擦劑之組合物中使用。於某些具體實施例 中,於本發明之潔齒劑組成物中存在之磨擦劑賦形劑^總量 係5重量%至60重量%。於某些具體實施例中,當該潔齒 劑組成物係一種牙膏時,磨擦劑賦形劑係以重量計1〇重量 %至55重量%之量存在。 3. 抗-微生物劑 適合於本發明中之使用之抗微生物劑包括非離子之抗菌 劑,其等包括經鹵化之二苯基醚化合物諸如2,4,4,-三氣-2,· 經基二笨基喊(二氣苯氧氣盼(Triclosan))及2,2,-二經基 ,5,5’-二溴二苯基醚。其他有用之非離子之抗菌劑包括酚系之 化合物,其等包括酚及其同系物、單及多烷基及芳族之鹵 酚、間苯二酚及其衍生物及雙酚之化合物,此等酚系之化合 物係於美國專利第5,368,844號中較完整地揭示,其揭示係 以引用之方式併入本文中。 於某些具體實施例中,一種根據本發明之口腔保健組成物 201102060 包含一種抗-微生物劑。於某些具體實施例 劑係-種自下列選出之分子:二氣苯氧氯 =1〇—)及其鹽(例如,其乙酸鹽、葡萄糖酸 風贱鹽)、過氧化物 '西分類及彼等之鹽、杜滅 c =芬(b_〇chlorophene)、鋅鹽、葉綠素、銅鹽、葡萄糖 -义鋼、銅葉綠素、硫酸月桂_、第四級單 :基=节基二甲基編赠鹽諸如氣 麵、及其寺之組合物。 於某些具體實施财,該抗微生物劑係— 於某些具體實施射,該非離子之抗菌_以^ 里/至5重量%之濃度包含於一種潔齒劑組成物中。於 些具體實施例中,該非離子之抗菌劑係以〇3 ^ 重量%之量存在。 .垔里/〇至1.2 4 · 彳/L· · 齒劑 一於某些具體實施例巾,-種根據本發明之口腔組成物包含 一種抗-齲齒劑。於某些具體實施例中,該抗-齲齒劑係一種 自下列選出之氟離子來源:無機之氟化物鹽,諸如可溶之鹼 金屬、驗土金屬鹽(例如,氣化納、氣化鉀、氣化銨、氣化 1)、一種銅氟化物諸如氟化亞銅、氟化鋅、氟化鋇、氟矽 酉欠鈉氟石夕酸知、氟錯酸鈉、氟錯酸銨、單氟磷酸鈉、單_ 及二-氟磷酸鋁、經氟化之焦磷酸鈉鈣、及其等之組合物。 5. 潔齒劑媒劑 於某些具體實施例中,一種根據本發明之口腔保健組成物 包含一種口腔可接受之潔齒劑媒劑。於某些具體實施例中, 17 201102060 該潔齒劑㈣於其中包含-種潤_。適合於本發明中之使 用之潤濕劑包括甘油、山梨醇、木糖醇、及/或於2〇〇至】〇〇〇 之範圍内之分子量之聚丙二醇。如於本文中使用,“山梨 醇”表示通常如-種70%水溶液市售之物質。於某些具體實 施例中,該淵濕劑濃度係口腔組成物之5重量%至7〇重量 %。 於某些具體實施例中,-種根據本發明之口腔保健組成物 包含水。於商業上適合之牙膏之製備中使用之水較佳地應係 已去離子的及不包含有機之雜質。於某些具體實施例中,水 係以該口腔組成物之15重量%至3G重量%之量存在。於某 些具體實施例中’水係以1G重量%之量存在。於某些具體 實施例中’此等量之水包括自由態之水,其係除了連同其他 物質一起諸如連同山梨醇一起引進者之外加入。 6. 界面活性劑 適合於本發明之組成物中之使用之界面活性劑包括具有 達成提高之預防疾病作用之能力及致使該口腔保健組成物 較化妝地可接文之任何物質。該界面活性劑較佳地係一種洗 淨之物質,其賦與該口腔保健組成物洗淨及發泡之性質。 於某些具體貫施例中,一種根據本發明之口腔保健組成物 包含一種界面活性劑。於某些具體實施例中,一種根據本發 明之口腔保健組成物包含界面活性劑類之一種組合物。於某 些具體實施例中,該界面活性劑係一種陰離子界面活性劑, 其包含硫酸高碳烧基酯鹽諸如硫酸月桂酯鈉。於某些具體實 施例中,該界面活性劑係一種自下列選出之與酵素相容之界 201102060 面活性劑:非陰離子之聚氧乙烯界面活性劑諸如Pluronic⑧ F127、P〇lyoxamer 407、Steareth 30、P〇lyS〇rbate 20 ;及兩性 之界面活性劑諸如揶油醯胺基丙基甜菜鹼及椰油醯胺基丙 基甜菜鹼月桂基葡萄糖苷。於某些具體實施例中,一種根據 本發明之口腔組成物以2重量%至1〇重量%之於潔齒劑組 成物中之總界面活性劑濃度包含一種界面活性劑或界面活 性劑之組合物。於某些具體實施例中,該界面活性劑或界面 活性劑之組合物以3.5重量%至6.5重量%重量比之量存在。 7· 抗-牙石劑 於某些具體貫施例中’ 一種根據本發明之口腔保健組成物 包含—種抗-牙石劑。於某些具體實施例中,該抗_牙石劑係 自下列選出:焦磷酸鹽,包括二鹼或四鹼金屬焦磷酸鹽諸如 Na4P2〇7 . k4P2〇7 ' Na2K2P2〇7 . Na2H2P2〇7^K2H2P2〇7 ; 酸鈉,長鏈聚填酸鹽諸如六偏磷酸鈉;及環狀之填酸鹽 諸=二偏磷酸鈉。於某些具體實施例中,該抗·牙石劑係以j 重量%至5重量%之濃度存在於本發明之一種潔齒劑組成物 中。 8· 增稠劑 於某些具體實施例中,一種根據本發明之口腔保健組成物 包含一種增稠劑。於某些具體實施例中,.該增稠劑係,但不 限於,由下列組成之群中選出:碳酸鈣、二氧化鈦、二氧化 矽、π石、氧化鋁、磷酸二鈣、磷酸三鈣、氫氡化鎂、纖維 素增稠劑諸如羧曱基纖維素、羥基烷基纖維素諸如羥基丙基 纖維素及羥基乙基纖維素、樹膠諸如黃原膠、聚二醇及聚乙 201102060 二醇、無機之增稠劑(例如,非晶形之矽石化合物、天然及 合成之黏土、矽酸鋰鎂及矽酸鎂鋁)、及其等之組合物。 於某些具體實施例中,該增稠劑係一種自下列選出之有機 增稠劑:天然及合成之樹膠及膠體,包括纖維素增稠劑諸如 羧曱基纖維素;羥基烷基纖維素諸如羥基丙基纖維素及羥基 乙基纖維素;膠類諸如黃原膠;於商品名稱P〇ly〇XTM下銷售 之變動之分子量之聚二醇;及聚乙二醇。於某些具體實施例 中’該增稠劑係一種自下列選出之無機之增稠劑:非晶形之 矽石化合物諸如於商品名稱Cab-o-Sil®下可獲得之膠體矽石 化合物(由 Cabot Corporation 製造及由 Lenape Chemical, Bound Brook,N.J.供銷)、Zeodent® 165 ( J.M. Huber Chemicals Division,Havre de Grace, Md. 21078)、Sylodent® 15 (Davision Chemical Division of W.R. Grace Corporation, Baltimore,Md. 21203)、天然及合成之黏土;矽酸經鎂(合 成鐘皂石(Laponite ))、及石夕酸鎂鋁(Veegum )。於某些具體 實施例中,該增稠劑係以0.1重量%至10重量%之量存在於本 發明之潔齒劑組成物中。於某些具體實施例中,該增稠劑係 以0.5重量%至4.0重量%之量存在。 9. 抗-氧化劑
於某些具體實施例中’根據本發明之口腔組成物包含一種 抗-氧化劑。於某些具體實施例中,該抗-氧化劑係自下列選 出:天然存在之生育酚類及彼等之衍生物類(例如,微生素 E乙酸鹽)、維生素C及其鹽類及衍生物類(例如,軟脂酸抗 壞血酸醋、填酸抗壞血酸酯鎮、乙酸抗壞血酸酯)、維生素A 20 201102060 及衍生物類(維生素A軟脂酸^旨)、生育三烯_、類黃嗣類、 阿伐-羥基酸類(例如,檸檬酸、乳酸、蘋果酸、酒石酸) 及彼等之鈉、鉀及鈣鹽類、類黃酮類、獬黃_、酚系苄基胺 類、五倍子酸丙酯、五倍子酸辛酯、五倍子酸十二酯、;基 羥基大茴香醚(BHA,E320 )、丁基羥基曱笨(BHT,2卜 二第二丁基-4-曱基酚,E321 )、卵鱗脂類、以檸檬酸酯化之 可食用之脂肪酸之單-及二甘油酯類、類胡蘿蔔素類、胡蘿 蔔素類(例如’ α ·胡蘿蔔素、/3 -胡蘿蔔素、番茄紅素)及 彼等之衍生物類、植酸、乳鐵蛋白、伸乙二胺四乙酸 (EDTA )、乙一醇雙(2-胺基乙基)醚-Ν,1ΝΓ,Ν,,Ν'-四乙酸 (EGTA)、葉酸及其衍生物類、泛醌及泛醇及彼等之衍生物 類、阿魏酸及其衍生物類、鋅及其衍生物類(例如,Zn〇、 Z11SO4)、砸及其衍生物類(例如’曱硫胺酸砸)、鱗酸類及 單磷酸之鈉、鉀及詞鹽類、及自植物(例如,茶、綠茶、藻 類、葡萄軒、小麥胚芽、甘菊、迷迭香、牛至)分離之其等 之成分、萃取物及餾分、及其等之組合物。 Π . 提供口腔保健利益之方法 於某些具體實施例中,本發明揭示一種提供口腔保健利益 之方法,其包含將一種包含治療有效量之至少一種式丨之碳 酸酯化合物及至少一種賦形劑之口腔組成物塗敷至口腔。於 某些具體實施例中,該等口腔保健利益包括生物膜抗_附 著、抗-氧化劑、及抗-微生物之利益。於某些具體實施例中, 一種提供口腔保健利益之方法包含將一種包含治療有效量 之至少一種式1之碳酸酯化合物及至少一種賦形劑之口腔組 21 201102060 成物塗敷至口腔,如先前於以上章節中討論β Α. 口腔生物膜抗-附著 口腔生物膜-包含細菌、細菌之細胞外之副產物、蛋白 質、月旨質、及醣脂質-係於口絲面上形紅減,其提供 用於結石或牙石形成之場所。 八 於某些具體實施例中,本發明揭示一種用於提供—種口腔 生物膜k·!1#著利益之方法。於某些具體實施例+,該提供 ^月:生物膜抗 P付著利益包含經由一種式工之碳酸酿化合 之群體密度感應抑制作用。於某些具體實施例中,該提: 之口腔生物膜抗-附著利益包含—種式ι之碳㈣化斑 I腔細菌交互作用以使其不能附著至口腔表面。於某些具體 貝知例中’-種式1之嚷酸§旨化合物與於口腔細菌之表 之黏附素、配位子及其他之分子㈣分(其料常協賴於 口,表面上之受體或其他之分子内部分之鍵聯)交互作用: 於某些具體貫施例中,該提供之口腔生物膜抗·附著利益包 含Γ種式1之碳酸sl化合物與口縣面交互作用以形成-種 保A層’致使細菌及生物膜組份不能附著至口腔或牙齒表 面’藉以避免於口腔表面形成—種最初之固著之層。於某些 具體貫施例中’-種“之碳酸gl化合物可實f地覆蓋口腔 表面,及避免生物縣質之細狀其他組份之附著。 &含治療有效里之至少_種本發明之碳酸酯4匕合物之口 M la成#; _抗_附著利益係使用結晶紫檢定(s 〇 p
No. ATO-3345-00)於〜種384井板( 384 weU中於 0.0004-2,500 ppm濃度範圍内研究。 22 201102060 B. 抗-氧化劑 氧化作用係自一種物質轉移電子至一種氧化劑之化學反 應及可產生自由基,該等自由基引發組織_傷害之連鎖反應 及發炎。氧化之壓迫力(oxidative stress)係於反應性氧之 製造與生物系統之迅速地解毒該等反應性之中間體或修補 造成之傷害之能力之間之不平衡之結果,及於許多疾病情況 中可係一種重要之因素。抗氧化劑係具有減缓或防止其他分 子之氧化作用之能力之還原劑。 於某些具體實施例中,本發明揭示一種用於提供一種抗_ 氧化劑利益之方法。於某些具體實施例中’該提供之抗-氧 化劑利益包含一種式1之碳酸酯化合物終止一種自由基連鎖 反應。於某些具體實施例中,一種Si之碳酸酯化合物移除 自由基中間體。於某些具體實施例中,一種式1之碳酸酯化 合物經由於不產生自由基情況下本身被氧化而抑制其他之 氧化反應。於某些具體實施例中,一種式1之碳酸酯化合物 提供一種與存在之抗·氧化劑可比較之抗-氧化劑利益功效。 於某些具體實施例中,一種式1之碳酸酯化合物提供一種與 維生素E可比較之抗-氧化劑利益功效。 抗-氧化劑活性係使用脂質過氧化物酶檢定(Kamiaya Biomedical Co.,Seattle,WA)而測定,其係測量氫過氧化異 丙本基團之還原作用之一種比色方法。 C· 抗-微生物 於某些具體實施例中,本發明揭示一種用於提供一種抗_ 微生物利益之方法。於某些具體實施例中,該提供之抗-微 23 201102060 生物利益包含一種式1之碳酸醋化合物擾亂微生物細胞膜 (microorganism plasma membrane)之脂質部分。於某些具 體實施例中’ 一種式1之碳酸醋化合物改變微生物膜之穿透 性’造成細胞内物質之漏泄及細胞死亡。於某些具體實施例 中,一種式1之碳酸酯化合物越過微生物之細胞膜^穿透進 入細胞之内部及與對於抗微生物之活性重要之細胞内之位 置交互作用。於某些具體貫施例中’該提供之抗_微生物利 益包含一種式1之碳酸酯化合物抑制口腔生物膜之形成。 抗-微生物之試驗係根據用於最低之抑制濃度(MIC)之測 定之SOP No.ATO-5308-OO測量。 Π . 調節牙周疾病代謝產物之方法 於齒齦裂隙之流體中之牙周疾病代謝產物對應於健康及/ 或牙周疾病口腔狀態,及容許口腔健康之鑑別之診斷。牙周 疾病代謝產物可係自下列選出:一種由胺基酸代謝作用產生 之化合物;一種於尿素循環中產生之化合物;一種於麵胱甘 肽轉化作用中產生之化合物;一種於脂質代謝作用中產生之 化合物;一種於碳水化合物代謝作用中產生之化合物;一種 由核酸代謝作用產生之化合物;維生素;及辅因子。 於本文中敍述之牙周疾病代謝產物係使用代謝體學輪廓 (metabolomic profiling)技術而發現。此等代謝體學輪廓技 術係於美國專利第7,005,225號及第7,329,489號;及美國專利 申請案第11/357,732號;第11/3〇1,〇77號(公告第 2006/0134676號);第 11/301,078 號(公告第 2006/0134677 號);第11/301,079號(公告第2006/0134678號)及第 24 201102060 11/405,033號(公告第2007/0072203號)中敍述,其等之完整 内容係藉此以引用之方式併入。 於某些具體實施例中,本發明揭示向上調節或向下調節牙 周疾病代謝產物之方法,其包含將一種包含治療有效量之至 少一種式1之碳酸酯化合物及至少一種賦形劑之口腔保健組 成物塗敷至口腔。於某些具體實施例中,該經向上調節或經 向:調節之代謝產物係至少—種自下列選出之化合物:一種 基1代4丨作用產生之化合物;—種於尿素循環中產生之 ’一種於麵胱甘肽轉化作用中產生之化合物;一種於 中產22==中產生之化合物;一種於碳水化合物代謝作用 ,化合物;一種由核酸代謝作用產生之化合物;維生 f ’及輔因子。 A. 向上調節 疾病實施例中,本發明揭示—制於向上調節牙周 節牙月广法勿之方法。於某些具體實施例中,該用於向上調 謝產物之方法包含將-種包含治療有效量之 組成物塗hTf31化合物及至少—種賦形劑之σ腔保健 疾病代謝產物些具體實施例中,該向上調節牙周 之包含治療有致量之S將種前於以上章節中討論 種賦形劑之D腔組之碳酸s旨化合物及至少一 該口腔保魏成物向上=至/腔。於某些具體實施例中, 甘肽、抗壞μ、及_^之麵胱甘肽、喊化之楚胱 25 201102060 B. 向下調節 於某些具體實施例中,本發明揭示一種用於向下調節牙周 疾病代謝產物之方法。於某些具體實施例中,該用於向下調 節牙周疾病代謝產物之方法包含將一種包含治療有效量之 至少一種式1之碳酸酯化合物及至少一種賦形劑之口腔保健 組成物塗敷至口腔。於某些具體實施例中,該向下調節牙周 疾病代謝產物之方法包含將一種如先前於以上章節中討論 之包含治療有效量之至少一種式1之碳酸酯化合物及至少一 種賦形劑之口腔組成物塗敷至口腔。於某些具體實施例中, 該口腔保健組成物向下調節至少一種由下列組成之基團中 選出之代謝產物:肌苷、次黃嘌呤、鳥苷、鳥嘌呤、白胺酸、 異白胺酸、離胺酸、曱硫胺酸、苯基丙胺酸、脯胺酸、絲胺 酸、蘇胺酸、色胺酸、酪胺酸、纈胺酸、苯基乙酸、α-羥 基異己酸、5-胺基正戊酸、膽鹼、丙三醇-3-磷酸酯、及Ν-乙醯基神經胺糖酸。 【實施方式】 實例 實例1 表1. 對於一組之三種包含碳酸酯分子内部分之化合物結 構之資訊及抗-生物膜/滅菌之活性。 化合物 分子 MBEC1 MIC2 量 (ppm)* (ppm)* 26 201102060 〇 OH 化合物58 258.35 156 625 OH 0 化合物59 294.39 78 156 0 y 化合物58 274.4 39 78 1MBEC=最低生物膜消除濃度(抗-生物膜) 2 MIC=最低抑制濃度(殺菌劑) *以奈斯隆氏放線菌生物膜之單一物種為基礎 實例2 於一種牙膏中調配之本發明之碳酸酯化合物具有向上調節 或向下調節至少一種自下列選出之分子之能力:一種由胺基 酸代謝作用產生之化合物;一種於尿素循環中產生之化合 物;一種於麩耽甘肽轉化作用中產生之化合物;一種於脂質 代謝作用中產生之化合物;一種於碳水化合物代謝作用中產 生之化合物;一種由核酸代謝作用產生之化合物;維生素; 及輔因子。 化合物58 如於以上之詳細敍述及實例中討論,以於一種牙膏中調配 27 201102060 之化合物58接觸口腔可向下調節一種或一種以上之下列代 謝產物之產生:肌苷、次黃°票呤、鳥苷、鳥嗓吟、白胺酸、 異白胺酸、離胺酸、曱硫胺酸、苯基丙胺酸、脯胺酸、絲胺 酸、蘇胺酸、色胺酸、酪胺酸、纈胺酸、苯基乙酸、羥 基異己酸、5-胺基正戊酸、膽驗、丙三醇-3-構酸S旨、及Ν-乙醯基神經胺糖酸。 以於一種牙膏中調配之化合物58接觸口腔可向上調節一 種或一種以上之下列代謝產物之產生:尿酸、經還原之麩胱 甘肽、經氧化之麩胱甘肽、抗壞血酸、及麩醯胺酸。 化合物59 如於以上之詳細敍述及實例中討論,以於一種牙膏中調配 之化合物59接觸口腔可向下調節一種或一種以上之下列代 謝產物之產生:肌苷、次黃嘌吟、鳥苷、鳥嘌吟、白胺酸、 異白胺酸、離胺酸、曱硫胺酸、苯基丙胺酸、脯胺酸、絲胺 酸、蘇胺酸、色胺酸、酪胺酸、纈胺酸、苯基乙酸、α -羥 基異己酸、5-胺基正戊酸、膽鹼、丙三醇-3-磷酸酯、及Ν-乙醯基神經胺糖酸。 以於一種牙膏中調配之化合物59接觸口腔可向上調節一 種或一種以上之下列代謝產物之產生:尿酸、經還原之麩胱 甘肽、經氧化之麩胱甘肽、抗壞血酸、及麩醯胺酸。 化合物60 如於以上之詳細敍述及實例中討論,以於一種牙膏中調配 之化合物60接觸口腔可向下調節一種或一種以上之下列代 謝產物之產生:肌苷、次黃σ票呤、鳥苷、鳥嘌吟、白胺酸、 28 201102060 異白胺酸、離胺酸、曱硫胺酸、苯基丙胺酸、脯胺酸、絲胺 酸、蘇胺酸、色胺酸、酪胺酸、纈胺酸、苯基乙酸、α -羥 基異己酸、5-胺基正戊酸、膽鹼、丙三醇-3-磷酸酯、及Ν-乙醯基神經胺糖酸。 以於一種牙膏中調配之化合物60接觸口腔可向上調節一 種或一種以上之下列代謝產物之產生:尿酸、經還原之麩胱 甘肽、經氧化之麩胱甘肽、抗壞血酸、及麩醯胺酸。 【圖式簡單說明】 無 【主要元件符號說明】 無 29
Claims (1)
- 201102060 七、申請專利範圍: 1. 一種口腔保健組成物,其包含治療有效量之至少一種式1 之碳酸酯化合物及至少一種賦形劑: Ri r2 〇 式1 其中, 心及R2獨立地係:脂族基團、羥基脂族基團、 或芳基基團。 2. 如申請專利範圍第1項之口腔保健組成物,其中仏及R2 獨立地係:環狀或分枝之脂族基團、線性或分枝之羥基脂 族基團、或未經取代之芳基基團。 3. 如申請專利範圍第2項之口腔保健組成物,其中&及R2 獨立地係:具有多達10個碳原子之環狀或分枝之脂族基 團、具有多達10個碳原子之線性或分枝之羥基脂族基團、 或未經取代之芳基基團。 4. 如申請專利範圍第3項之口腔保健組成物,其中心係自具 有多達10個碳原子之環狀或分枝之脂族基團選出。 5. 如申請專利範圍第4項之口腔保健組成物,其中R2係自線 性或分枝之羥基脂族基團選出。 6. 如申請專利範圍第3項之口腔保健組成物,其中R!係未經 取代之芳基基團。 7. 如申請專利範圍第6項之口腔保健組成物,其中R2係具有 多達10個碳原子之線性或分枝之羥基脂族基團。 201102060 8.如申請專利範圍第1項之口腔保健組成物,其中該至少一 種式1之碳酸酯化合物係:9.如申請專利範圍第2項之口腔保健組成物,其中該至少一 種式1之碳酸酯化合物係:10.如申請專利範圍第2項之口腔保健組成物,其中該至少一 種式1之碳酸酯化合物係:OH 11.如申請專利範圍第2項之口腔保健組成物,其中至少一種 賦形劑係由下列組成之群中選出:界面活性劑、減敏感 劑、增白劑、牙石控制劑、抗菌劑、包括石夕石之磨擦劑、 黏合劑及增稠劑、清潔劑、黏附劑、泡沫調節劑、pH修 飾劑、口腔-感覺劑、增甜劑、調味劑、著色劑、防腐劑、 其等之組合物、及其類似物。 31 201102060 12. —種提供口腔保健利益之方法,其包含將一種包含治療有 效量之至少一種式i之碳酸酯化合物及至少—種賦形劑 之口腔保健組成物塗敷至口腔。 利範圍第12項之方法,其中至少—種口腔保健 凰’、下列組成之群中選出:生物膜抗_P付著、抗 劑、及抗-微生物利兴。 f抗乳化 其中該口腔保健利益係 其中該口腔保健利益係 其中該口腔保健利益係 14·=請專利範圍第二員之方法 生物膜抗-附著。 15. 巧專利範圍第13項之方法 抗_氧化劑。 16. 利範圍第13項之方法 抗-微生物。 17. —種向上調節或向 含將-種包含治淨右/1周疾病代謝產物之方法’其包 物及至少-種觥:效5之至少一種式1之碳酸酉旨化合 18·如中請專利_第1之口腔保健組成物塗敷至口腔。 向上調節或向下士貝之方法’其中該口腔保健組成物 由胺基酸代謝作二下列選出之分子一種 生之化合物、〜接 合物、一種於尿素循環中產 物、一種於脂質耽甘㈣化作用中產生之化合 化合物代謝作用^用中產生之化合物、—種於碳水 產生之化合物、之化合物、—種由㈣代謝作用 19·如申請專利範 向上調節至少1 ^方法,其中該口腔保健組成物 顸自下列選出之代謝產物:尿酸、經還 32 201102060 原之麩胱甘肽、經氧化之麩胱甘肽、抗壞血酸、及麩醯 胺酸。 20.如申請專利範圍第18項之方法,其中該口腔保健組成物 向下調節至少一種自下列選出之代謝產物:肌苷、次黃 嘌呤、鳥苷、鳥嘌呤、白胺酸、異白胺酸、離胺酸、曱 硫胺酸、苯基丙胺酸、脯胺酸、絲胺酸、蘇胺酸、色胺 酸、酪胺酸、纈胺酸、苯基乙酸、羥基異己酸、5-胺 基正戊酸、膽鹼、丙三醇-3-磷酸酯、及Ν-乙醯基神經胺 糖酸。 33 201102060 四、指定代表圖: (一) 本案指定代表圖為:第(無)圖。 (二) 本代表圖之元件符號簡單說明: 無 五、本案若有化學式時,請揭示最能顯示發明特徵的化學式: 無 4
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2009/039140 WO2010114533A1 (en) | 2009-04-01 | 2009-04-01 | Anti-biofilm carbonate compounds for use in oral care compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201102060A true TW201102060A (en) | 2011-01-16 |
TWI481402B TWI481402B (zh) | 2015-04-21 |
Family
ID=41198620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW099109766A TWI481402B (zh) | 2009-04-01 | 2010-03-31 | 用於口腔保健組成物之抗-生物膜碳酸酯化合物 |
Country Status (14)
Country | Link |
---|---|
US (1) | US8617523B2 (zh) |
EP (1) | EP2413927B1 (zh) |
JP (1) | JP2012522771A (zh) |
CN (1) | CN102378629B (zh) |
AR (1) | AR078318A1 (zh) |
AU (1) | AU2009343748B2 (zh) |
BR (1) | BRPI0924882A2 (zh) |
CA (1) | CA2753658C (zh) |
MX (1) | MX2011008959A (zh) |
MY (1) | MY163501A (zh) |
RU (1) | RU2526912C2 (zh) |
SG (1) | SG173744A1 (zh) |
TW (1) | TWI481402B (zh) |
WO (1) | WO2010114533A1 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2463181B (en) | 2007-05-14 | 2013-03-27 | Univ New York State Res Found | Induction of a physiological dispersion response in bacterial cells in a biofilm |
JP2012097035A (ja) * | 2010-11-02 | 2012-05-24 | Kao Corp | オートインデューサー−2阻害剤、並びに歯周病の予防及び/又は治療剤 |
TWI415572B (zh) | 2011-06-17 | 2013-11-21 | Univ Chang Gung | 利用1,2,3,4,6-五-o-沒食子醯基-d-葡哌喃糖來抑制生物膜形成 |
JP6016343B2 (ja) * | 2011-09-08 | 2016-10-26 | 株式会社ロッテ | 口腔用組成物 |
KR20150097495A (ko) | 2012-12-19 | 2015-08-26 | 콜게이트-파아므올리브캄파니 | 구강 관리 조성물 |
TW201620487A (zh) | 2014-11-14 | 2016-06-16 | 美國棕欖公司 | 含鋅鹽與碳酸鈣之口腔護理組成物 |
CA3039062A1 (en) | 2016-10-20 | 2018-04-26 | Colgate-Palmolive Company | Antimicrobial compositions for oral care or cleansing, and methods for anti-attachment polymers and coatings |
WO2019121440A1 (en) * | 2017-12-22 | 2019-06-27 | Unilever N.V. | An antimicrobial composition |
US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3538230A (en) | 1966-12-05 | 1970-11-03 | Lever Brothers Ltd | Oral compositions containing silica xerogels as cleaning and polishing agents |
US4358437A (en) | 1978-11-29 | 1982-11-09 | Beecham Group Limited | Compositions |
US5288480A (en) | 1987-01-30 | 1994-02-22 | Colgate-Palmolive Co. | Antiplaque antibacterial oral composition |
GB9117140D0 (en) | 1991-08-08 | 1991-09-25 | Unilever Plc | Treatment of periodontitis |
DE4226043A1 (de) * | 1992-08-06 | 1994-02-10 | Haarmann & Reimer Gmbh | Mittel mit physiologischem Kühleffekt und für diese Mittel geeignete wirksame Verbindungen |
WO1995013094A1 (en) | 1993-11-10 | 1995-05-18 | Bristol-Myers Squibb Company | Treatment of bacterially-induced inflammatory diseases |
US5578295A (en) | 1995-04-28 | 1996-11-26 | The Procter & Gamble Company | Oral care compositions comprising certain substituted diphenyl ethers |
DE19623383C2 (de) * | 1996-06-12 | 1999-07-01 | Henkel Kgaa | Verwendung von Fettstoffen als Siliconersatz zur Herstellung von kosmetischen und/oder pharmazeutischen Zubereitungen |
JP2000512285A (ja) | 1996-06-12 | 2000-09-19 | ヘンケル・コマンディットゲゼルシャフト・アウフ・アクチエン | 化粧品および/または薬剤製剤 |
FR2794457B1 (fr) * | 1999-06-01 | 2001-08-10 | Oreal | Derives carbonates de retinol, procede de preparation et utilisations |
ES2395991T3 (es) | 1999-12-03 | 2013-02-18 | Baxter International Inc. | Ensayo de pirogenicidad para su uso con sistemas de inmunoensayo automáticos |
GB0001704D0 (en) | 2000-01-25 | 2000-03-15 | Glaxo Group Ltd | Protein |
EP1285092A4 (en) | 2000-04-14 | 2003-07-16 | Metabolon Inc | METHOD FOR DISCOVERY OF MEDICINES, DISEASE TREATMENT AND DIAGNOSIS USE THE METABOLOMICS |
US7329489B2 (en) | 2000-04-14 | 2008-02-12 | Matabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
US6500409B1 (en) | 2000-05-10 | 2002-12-31 | Colgate Palmolive Company | Synergistic antiplaque/antigingivitis oral composition |
DE10059584A1 (de) * | 2000-11-30 | 2002-06-06 | Beiersdorf Ag | Kosmetische oder dermatologische getränkte Tücher |
US7005225B2 (en) | 2002-11-12 | 2006-02-28 | Samsung Electronics Company | Organosol including amphipathic copolymeric binder having crystalline material, and use of the organosol to make dry tones for electrographic applications |
US20040224876A1 (en) | 2003-02-14 | 2004-11-11 | Jost-Price Edward Roydon | Combination therapy for the treatment of immunoinflammatory disorders |
EP1466949A1 (en) * | 2003-04-10 | 2004-10-13 | Symrise GmbH & Co. KG | Non-toxic coating composition, methods of use thereof and articles protected from attachment of biofouling organisms |
GB2401865A (en) * | 2003-05-22 | 2004-11-24 | Givaudan Sa | Antibacterial and antifungal glycerol monocarbonates |
DE10341699A1 (de) * | 2003-09-10 | 2005-04-28 | Symrise Gmbh & Co Kg | Verfahren zur Herstellung unsymmetrischer Kohlensäureester |
EP1697389A4 (en) | 2003-10-24 | 2008-12-24 | Eisai R&D Man Co Ltd | COMPOUNDS AND METHODS FOR TREATING ILLNESS AND SUFFERING TOLL-LIKE RECEPTOR 2 RELATED DISORDERS |
JP2007519894A (ja) | 2003-12-03 | 2007-07-19 | ホワイトヘッド インスティテュート フォー バイオメディカル リサーチ | 標的としてのカドヘリンの使用 |
FI20040572A0 (fi) | 2004-04-23 | 2004-04-23 | Ctt Cancer Targeting Tech Oy | Matriisi-metalloproteinaasin aktiviteetin inhibiittorit |
US20090203776A1 (en) * | 2004-09-23 | 2009-08-13 | Matias Jonathan R | Methods of using menthol propyleneglycol-carbonate and analogs thereof for producing anti-inflammatory and anti-angiogenic effects |
US20060141421A1 (en) | 2004-12-28 | 2006-06-29 | Kimberly-Clark Worldwide, Inc. | System and method for detecting substances related to oral health |
WO2006074450A2 (en) | 2005-01-07 | 2006-07-13 | President And Fellows Of Harvard College | Methods and compositions for detecting and modulating periodontal disorders and periodontal diseases |
JP2009523029A (ja) | 2006-01-10 | 2009-06-18 | コルゲート・パーモリブ・カンパニー | 炎症の予防または軽減のために、細胞表面受容体を調節する方法 |
US20080161394A1 (en) | 2006-11-23 | 2008-07-03 | Jean-Yves Fouron | Cosmetic composition comprising at least one volatile carbonic acid ester |
WO2008093072A2 (en) * | 2007-01-29 | 2008-08-07 | Paul Webb | Topical composition against contact dermatitis due to water |
EP2207546A1 (en) * | 2007-10-09 | 2010-07-21 | Humco Holding Group, Inc. | Antifungal treatment of nails |
-
2009
- 2009-04-01 AU AU2009343748A patent/AU2009343748B2/en not_active Ceased
- 2009-04-01 MY MYPI2011003958A patent/MY163501A/en unknown
- 2009-04-01 CN CN200980158592.7A patent/CN102378629B/zh not_active Expired - Fee Related
- 2009-04-01 BR BRPI0924882-0A patent/BRPI0924882A2/pt not_active IP Right Cessation
- 2009-04-01 WO PCT/US2009/039140 patent/WO2010114533A1/en active Application Filing
- 2009-04-01 EP EP09789558.5A patent/EP2413927B1/en active Active
- 2009-04-01 US US13/260,920 patent/US8617523B2/en active Active
- 2009-04-01 SG SG2011059318A patent/SG173744A1/en unknown
- 2009-04-01 CA CA2753658A patent/CA2753658C/en not_active Expired - Fee Related
- 2009-04-01 JP JP2012503386A patent/JP2012522771A/ja active Pending
- 2009-04-01 RU RU2011144093/15A patent/RU2526912C2/ru not_active IP Right Cessation
- 2009-04-01 MX MX2011008959A patent/MX2011008959A/es active IP Right Grant
-
2010
- 2010-03-31 TW TW099109766A patent/TWI481402B/zh not_active IP Right Cessation
- 2010-03-31 AR ARP100101098A patent/AR078318A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP2413927A1 (en) | 2012-02-08 |
CN102378629A (zh) | 2012-03-14 |
WO2010114533A1 (en) | 2010-10-07 |
MX2011008959A (es) | 2011-09-27 |
RU2526912C2 (ru) | 2014-08-27 |
EP2413927B1 (en) | 2018-01-24 |
SG173744A1 (en) | 2011-09-29 |
MY163501A (en) | 2017-09-15 |
CN102378629B (zh) | 2016-08-17 |
TWI481402B (zh) | 2015-04-21 |
AU2009343748A1 (en) | 2011-09-01 |
BRPI0924882A2 (pt) | 2015-07-07 |
JP2012522771A (ja) | 2012-09-27 |
US8617523B2 (en) | 2013-12-31 |
US20120020896A1 (en) | 2012-01-26 |
AU2009343748B2 (en) | 2013-01-31 |
CA2753658C (en) | 2014-10-28 |
CA2753658A1 (en) | 2010-10-07 |
AR078318A1 (es) | 2011-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201102060A (en) | Anti-biofilm carbonate compounds for use in oral care compositions | |
RU2448711C2 (ru) | Композиции для ухода за полостью рта, содержащие комбинации антибактериальных агентов и агентов, изменяющих реакцию организма-носителя | |
CA2431044A1 (en) | Oral compositions and use thereof | |
RU2492857C2 (ru) | Соединения - производные ментола и их применение в качестве активных системных агентов и агентов для ротовой полости | |
TW201338796A (zh) | 包含沒食子酸酯及沒食子醯胺之組成物 | |
JP5054914B2 (ja) | 口腔用組成物 | |
EP3397592B1 (en) | Mucin coated silica for bacterial aggregation | |
CA2934484A1 (en) | Oral care compositions comprising an acrylate/methacrylate/hydroxyethyl methacrylate phosphate copolymer | |
TWI511748B (zh) | 含有去氧糖抗代謝物質之口腔護理組成物 | |
JP2001089383A (ja) | 口腔用及び眼科用組成物 | |
JP2005239653A (ja) | 口腔用組成物 | |
KR101617845B1 (ko) | 치주 질환의 예방 및 개선용 조성물 | |
TWI532503B (zh) | 口腔保健組成物 | |
JP4344844B2 (ja) | 口腔用組成物 | |
JP4648293B2 (ja) | 口腔用組成物 | |
JP2017007992A (ja) | 口腔用組成物及びその殺菌力向上方法 | |
KR20170076421A (ko) | 폴리크레줄렌 및 불화화합물을 포함하는 구강용 조성물 | |
JP2001131040A (ja) | う蝕誘発性細菌増殖抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |